PR Newswire BiotechOriginal article
BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline
ALE1Positive
AI Analysis
Summary
BioMarin Pharmaceutical to acquire Alesta Therapeutics for $275 million upfront plus milestone payments to gain ALE1, a potential first oral therapy for hypophosphatasia. The acquisition will add ALE1 as a clinical program to BioMarin's pipeline.
Outcome Details
BioMarin to acquire Alesta Therapeutics for $275 million upfront plus milestone payments
Importance:7/10
Sentiment:
0.70
M&Aacquisitionoral therapypipeline expansionrare diseasehypophosphatasia
Related Companies
Read the original article
Published by PR Newswire Biotech on August 18, 2026 12:30 PM